Hainan Poly Pharm. Co., Ltd.

On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Hainan Poly Pharm. Co., Ltd.

32 YRS

Hainan, China

CNY 437.0 Million

43290 m²

500-1000 people

Main Products: Desloratadine / Dobutamine Hydrochloride / Trimebutine Maleate Salt / Esomeprazole / Acyclovir Sodium / Ganciclovir / Ganciclovir Sodium / Oxybutynin / Memantine Hydrochloride / Tetraxetan / Trimethoxy Dobutamine Hydrochloride / Beta-D-Ribofuranose 1,2,3,5-Tetraacetate / N2,9-Diacetylguanine / 4-(1-Bromoethyl)-6-Chloro-5-Fluoropyrimidine

Hainan, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

VERIFIEDMANUFACTURINGCOMPANY

Business Type

Manufacturing

Total Employees

500-1000 People

Plant Size

65 Acres

Total Annual Revenue

CNY 1189 Million

Production Experience

32+ Years

MAIN
PRODUCTS

1/3

Desloratadine

CAS: 100643-71-8

Packing: 25 KG/Fibre Drum

Lead Time: In Stock

Inquiry

1/3

Dobutamine Hydrochloride

CAS: 49745-95-1

Packing: 25 KG/Fibre Drum

Lead Time: 14-30 days

Inquiry

1/3

Trimebutine Maleate Salt

CAS: 34140-59-5

Packing: 25 KG/Fibre Drum

Lead Time: 14-30 days

Inquiry

ABOUT US

Hainan Poly Pharm. Co., Ltd.

Hainan Poly Pharm Co. Ltd. is a generics firm in China，dedicated to providing therapeutic-value products and services to patients and customers around the world, which mainly involves in the activities of R&D, manufacturing and marketing. Founded in 1992, Poly has built up an excellent product portfolio with producing both Active Pharmaceutical Ingredient (API) and finished products, and gained great reputation for its high-quality products. Poly initiated its international registration program in 2005. Since 2012, Poly has received inspections from authorities including US FDA, EU EMA, NMPA and WHO with positive outcoming, which has provided sound evidence of Poly's GMP compliance in practice and its efforts in quality control. With the approval of products for marketing by EU EMA and US FDA, and distribution of its products to EU markets, Poly has already marched into the global market. In 2017, Poly Pharm successfully completed Initial Public Offering (IPO) and listed in Shenzhen Stock Exchange ( 300630.SZ)